Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
AssigneeInnate Pharma
InventorsFrancois Romagne, Pascale Andre
Life of this patent
Estimating the term…
Abstract
This invention relates to compounds that inhibit KIR2DL1, 2 and/or 3 polypeptide comprising compounds (e.g., anti-KIR2DL1, 2, and/or 3 antibodies) that neutralize NK cell inhibitory receptors and methods of using such compounds and compositions containing in the treatment and prevention of inflammatory or autoimmune disorders.
Claims35
A method for treating an autoimmune disorder mediated by T cells, comprising administering to an individual in need thereof an effective amount of an antibody or antigen-binding fragment thereof that potentiates the cytotoxic activity of NK cells by blocking or neutralizing NK cell inhibition mediated by a KIR2DL1, KIR2DL2, and/or KIR2DL3 polypeptide, thereby reducing the number of T cells involved in mediating the autoimmune disorder.
Dependencies are inferred from the claim text.